Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Transmitted antiretroviral drug resistance in newly HIV-Infected and untreated patients in ségou and bamako, mali
AIDS Research and Human Retroviruses, Volume 29, No. 1, Year 2013
Notification
URL copied to clipboard!
Description
The WHO recommends regular surveillance for transmitted antiretroviral drug-resistant viruses in HIV antiretroviral treatment (ART)-naive patients in resource-limited settings. This study aimed to assess the prevalence of mutations associated with resistance in ART-naive patients newly diagnosed with HIV in Bamako and Ségou in Mali. HIV-positive patients who never received ART were recruited in Bamako and Ségou, Mali. The reverse transcriptase (RT) and protease (PR) genes of these patients were sequenced by the "ViroSeq" method. Analysis and interpretation of the resistance were made according to the WHO 2009 list of drug resistance mutations. In all, 51/54 (94.4%) sample patients were sequenced. The median age (IQR) of our patients was 24 (22-27) years and the median CD4 count was 380 (340-456) cells/mm 3. The predominant subtype was recombinant HIV-1 CRF02-AG (66.7%) followed by CRF06-cpx (12%) and CRF09-cpx (4%). Four patients had mutations associated with resistance, giving an overall prevalence of resistance estimated at 7.9%. There were two (4%) patients with nucleoside reverse transcriptase inhibitor (NRTI) mutations (one M184V and one T215Y), two (4%) with non-NRTI mutations (two K103N), and one (2%) with a protease inhibitor mutation (one I54V). The prevalence of primary resistance in newly infected patients in Mali is moderate (7.9%). This indicates that the standard NNRTI-based first-line regimen used in Mali is suboptimal for some patients. This study should be done regularly to inform clinical practice. © Copyright 2013, Mary Ann Liebert, Inc. 2013.
Authors & Co-Authors
Maïga, Almoustapha Issiaka
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
Fofana, Djeneba Bocar
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Maiga, Aichatou Chehy
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
Diallo, Fodié B.
Mali, Bamako
Arcac-sida-cesac
Aït-Arkoub, Zaïna
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Daou, Fatoumata
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
Cissé, Mamadou C.
Mali, Bamako
Arcac-sida-cesac
Sarro, Yeya Dit Sadio
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
Oumar, Aboubacar Alassane
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
Sylla, Aliou O.
Mali, Bamako
Cellule Sectorielle de Lutte Contre le Sida
Katlama, Christine
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Taiwo, Babafemi Olapoju
United States, Evanston
Northwestern University
Murphy, Robert L.
United States, Evanston
Northwestern University
Tounkara, Anatole
Mali, Bamako
Université Des Sciences Des Techniques et Des Technologies
Marcelin, Anne Geneviève
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Calvez, Vincent
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Statistics
Citations: 16
Authors: 16
Affiliations: 5
Identifiers
Doi:
10.1089/aid.2012.0118
ISSN:
08892229
e-ISSN:
19318405
Research Areas
Cancer
Infectious Diseases
Study Design
Cross Sectional Study
Study Locations
Mali